Navigation Links
Abaxis Animal Health Announces the Addition of a Feline Heartworm Application to the Rapid Diagnostics Product Line
Date:12/22/2011

UNION CITY, Calif., Dec. 22, 2011 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point of care instrumentation and consumables to the medical, research and veterinary markets, announced today the addition of a feline heartworm rapid test to their growing rapid diagnostics product line. The USDA has now approved the use of the Abaxis VetScan Canine Heartworm Antigen Test for feline applications. Abaxis anticipates shipping the product with its new application in January of 2012.

 

The addition of the feline heartworm claim represents the latest addition to a product line that already includes the VetScan Canine Heartworm Test, VetScan Canine Parvovirus Rapid Test and the VetScan Giardia Rapid Test.  Michael Solomon, Director of Business Development for North America Animal Health, commented, "Adding the feline claim to the already well accepted VetScan Canine Heartworm Test allows the veterinarian the flexibility to use the same product they already purchase and trust for both their canine and feline patients."

 

Gary Norsworthy, DVM and owner of the Alamo Feline Health Center in San Antonio, Texas, adds: "The ability to confidently identify adult heartworm infection in the cat with an antigen test provides the practitioner with an invaluable tool to positively diagnose the cause of respiratory presentations. While a negative test does not rule out the presence of adult heartworms and heartworm disease, a positive antigen test allows the veterinarian to provide a definitive diagnosis and prognosis, develop an appropriate treatment protocol and communicate this with the client with a high level of confidence."

 

"Abaxis continues to add important diagnostic tests to our overall product portfolio. The addition of these tests, along with Abaxis Veterinary Reference Laboratory now fully operational, allows the veterinary community to continue to deliver high-qualit
'/>"/>

SOURCE Abaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abaxis, Inc. to Present at the 23rd Annual Piper Jaffray Health Care Conference
2. Abaxis, Inc. to Present at Stephens, Inc. 2011 Fall Investment Conference
3. Abaxis, Inc. to Present at Sidoti & Companys New York II Emerging Growth Institutional Investor Forum
4. Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012
5. Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011
6. Abaxis, Inc. to Present at CL Kings 9th Annual Best Ideas Conference 2011
7. Abaxis to Present at 2011 Morgan Stanley Global Healthcare Unplugged Conference
8. Abaxis Announces Stock Repurchase Program
9. Abaxis Reports Financial Performance for the First Quarter of Fiscal 2012
10. Abaxis to Report First Quarter Fiscal Year 2012 Financial Results Thursday, July 28, 2011
11. Abaxis to Present at Jefferies 2011 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
(Date:10/20/2014)... MOUNTAIN VIEW, Calif. , Oct. 20, 2014 /PRNewswire/ ... field of interventional pulmonology, today announced completion of enrollment ... schedule.  The RENEW Clinical Study is the FDA-approved IDE ... treatment for severe emphysema. It was anticipated ... US in February 2013, would take until the end ...
(Date:10/20/2014)... Oct. 20, 2014  Indianapolis interventional medical device ... Toronto -based 3D visualization leader Synaptive ... Neurological Surgeons Annual Meeting that they have joined ... surgery. The collaboration is the first of its ... improve patient outcomes. NICO,s BrainPath® interventional access technology ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... , , ... ... Presented at American College of Cardiology Meeting,in Atlanta and Published in the Lancet , ... ...
... U.S. Cancer Centers Involved , ... , , ... ... HUNTINGTON BEACH, California and AMSTERDAM , ...
Cached Medicine Technology:Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 2Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 3Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 4Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 5Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 6Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 2Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 3Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 4Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 5
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... 2014 Allegheny General Hospital’s (AGH) Cardiovascular ... physicians to repair a damaged mitral valve as the ... system, developed by Abbott Vascular , is designed ... life-threatening condition in which the heart’s mitral valve leaflets ... from the heart’s left ventricle into the left atrium. ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
(Date:10/20/2014)... T.E.N., a technology and information ... that William H. Murray, renowned author and industry ... Leadership Award winner. Presented annually, the ISE® Luminary ... leader and industry practitioner for his or her ... information security industry. , Formerly with IBM, Murray ...
Breaking Medicine News(10 mins):Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... in Vietnam, The Nha Trang Institute of Vaccines and ... produced 5,000 doses of a H5N1 vaccine for// humans ... tested on white mice, guinea-pigs and cockerels and similar ... National Institute of Verification of Vaccines and Biological Products. ...
... human brain unique? Of the many explanations that can be ... myelin.// ,Conventional wisdom holds that myelin, the sheet ... fiber that conducts the neuron’s electrical impulses — is akin ... efficient signaling. But the research of UCLA neurology professor George ...
... delivered a male child on Wednesday at Holtz Children's Hospital. ... Ectopia// cordis. Seven or eight babies in a million are ... Naseem, was born with his heart outside his chest. The ... heart called pericardium had not developed in him. ...
... number of pounds women put on as they age, according ... by an Indian-American doctor.//,In a study that followed more than ... Dr Sanjay Patel of Case Western Reserve University in Cleveland ... put on less weight during middle age. ,The findings ...
... book is here that would thrill every gourmet. It is ... the year. It is a full course meal, daubed in ... goals. ,Brian Wansink is the brain behind this unique ... University Food and Brand Laboratory. Truly a gourmet, who enjoys ...
... a study shed light on a nagging mystery in neurobiology: ... pools of free zinc ions. Zinc - a new key ... signaling in the brain and spinal cord – says the ... affecting a neuronal zinc target, researchers have demonstrated a central ...
Cached Medicine News:Health News:Blame Myelin for Many Neuropsychiatric Disorders 2Health News:Naseem’s Heart Put In Its Plac 2Health News:Whet your appetite with “Mindless Eating”: A gourmet's deligh 2Health News:Whet your appetite with “Mindless Eating”: A gourmet's deligh 3Health News:Zinc – A New Key Player In Brain Circuitr 2
... ReZoom intraocular lens is a second-generation ... patients with greater independence from glasses than ... provides a range of vision that monfocals ... Optics technology distributes light over five optic ...
... best potential for quality vision with ACRYSOF ... for spherical aberration by addressing the effects ... accomplished without increasing edge thickness. Human ... design that provides improved image quality.,MTF (measured ...
... FRx Defibrillator was designed to be as ... Defibrillator and shares many of its features, ... The Philips HeartStart Home Defibrillator is an ... for home use by untrained users. Although ...
Designed to meet the demanding requirements of scientific and laboratory,applications. Special cabinet incorporates industrial quality with a,heavy duty refrigeration system to maintain your valu...
Medicine Products: